Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) Scores Positive CHMP Opinion for CSU in Europe
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of dupilumab (Dupixent, Regeneron & Sanofi) in the European Union (EU) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents.